Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04911374
Other study ID # C20-D134
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date September 11, 2020
Est. completion date February 3, 2021

Study information

Verified date September 2021
Source Revision Skincare
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This single-center clinical trial is being conducted to assess the efficacy and tolerability of an anti-aging eye cream and face moisturizer when used over the course of 12 weeks twice-daily by women, 35-65 years, with mild to moderate droopy eyelids, moderate crow's feet wrinkles, and moderate global facial photodamage.


Description:

This was an institutional review board (IRB)-approved study. Female subjects, 35-65 years of age, Fitzpatrick skin type I-VI, with mild to moderate droopy eyelids, moderate crow's feet wrinkles, and moderate global photodamage were recruited. Subjects applied a multi-ingredient anti-aging face moisturizer and eye twice-daily for 12 weeks. Subjects were provided with a gentle cleansing lotion and a sunscreen SPF 40+ to be utilized during the course of the study. Clinical grading of efficacy and tolerability parameters, VISIA-CR imaging, raking light VISIA analysis, skin pH, Tewameter, and pinch recoil measurements were performed at baseline, weeks 4, 8, and 12. Optical coherence tomography (OCT) imaging was performed at baseline and week 12. A total of 42 subjects completed the study.


Recruitment information / eligibility

Status Completed
Enrollment 45
Est. completion date February 3, 2021
Est. primary completion date December 22, 2020
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 35 Years to 65 Years
Eligibility Inclusion Criteria: - Women between the ages of 35 and 65 years - Women with Fitzpatrick skin type I-VI - Subjects must have mild to droopy eyelids, moderate crow's feet wrinkles, and moderate photodamage - Subjects must have no known medical conditions that, in the investigator's opinion, may interfere with study participation. - Subjects must be willing to provide verbal understanding and written informed consent. Exclusion Criteria: - Subjects which had a health condition and/or pre-existent dormant dermatological disease on the face - Subjects that had any invasive or non-invasive skin treatments, or invasive medical procedures three months prior to the study - Subjects that are unwilling to comply with the protocol - Female subjects who are pregnant, breast feeding, or planning a pregnancy. - Subjects who have any dermatological disorder, which in the investigator's opinion, may interfere with the accurate evaluation of the subject's skin, including rosacea, acne, and excessively oily or dry skin. - Subjects who have demonstrated a previous hypersensitivity reaction to any of the ingredients of the study products. - Subjects use of any medications that are known to potentially cause changes in the facial skin as determined by the Investigator. - Subjects who spend excessive time out in the sun.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Gentle Cleansing Lotion, Revision Skincare
Gentle cleansing lotion to be used by study participants
Aveeno Face Milk SPF 40+
Sunscreen to be applied after application of face moisturizer and eye cream in the morning. Participants were asked to apply the sunscreen if sun exposure was more than 30 minutes per day.

Locations

Country Name City State
United States Stephens and Associates Richardson Texas

Sponsors (1)

Lead Sponsor Collaborator
Revision Skincare

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Self-Assessment Questionnaire The secondary efficacy endpoints will be the Self-Assessment Questionnaire and the Subject Treatment Satisfaction and Ease of Use Questionnaire. A change in response values at week 4, week 8 and week 12 indicates an improvement compared to baseline response values. Subjects are asked to rate based on a scoring system of the following: from 5 (completely agree) to 1 (completely disagree). The best outcome is to Completely Agree with the statement/ question being asked. 12 weeks
Primary Improvement of Clinical Efficacy Parameters at 4, 8, and 12 weeks versus Baseline The primary efficacy endpoint will be the Investigator Clinical Grading using Modified Griffith's 10-point Scale. A change in scores at week 4, week 8 and week 12 in comparison to baseline indicates an improvement for the indicated parameter.
The efficacy parameters will be assessed globally on each subject's face using a modified Griffiths' 10-point scale according to the following numerical definitions (half-point scores may be used as necessary to more accurately describe the skin condition): 0 = none (best possible condition); 1 to 3 = mild; 4 to 6 = moderate;7 to 9 = severe (worst possible condition). The lower the score equates to the best possible outcome.
12 weeks
Primary Lack of Significant Increase in Objective Tolerability Parameters at week 4, 8, 12 compared to Baseline The primary tolerability endpoint will be the Investigator Tolerability Assessment of Erythema, Edema and Dryness. A change in scores or lack of significant change at week 4, week 8 and week 12 in comparison to Baseline indicates tolerability/safety of the test material. Four point scale with a lower score indicating a better outcome.
Example for Erythema: Erythema 0 = None No erythema of the treatment area
= Mild Slight, but definite redness of the treatment area
= Moderate Definite redness of the treatment area
= Severe Marked redness of the treatment area
12 weeks
Secondary Lack of Significant Increase in Subjective Tolerability Parameters at week 4, 8, 12 compared to Baseline The secondary tolerability endpoint will be the Subject Tolerability Assessment of Burning, Itching and Stinging. A change in scores or lack of significant change at week 4, week 8 and week 12 in comparison to Baseline indicates tolerability/safety of the test material. Four point scale with a lower score indicating a better outcome.
Example Burning. 0 = None No burning of the treatment area
= Mild Slight burning sensation of the treatment area; not really bothersome
= Moderate Definite warm, burning of the treatment area that is somewhat bothersome.
= Severe Hot burning sensation of the treatment area that causes definite discomfort and may interrupt daily activities and/or sleep
12 weeks
Secondary Decrease in transepidermal water loss at weeks 4, 8, and 12 versus baseline • Tewameter Measurements at baseline and weeks 4, 8, and 12. A change in Tewameter values reflects an improvement in the barrier properties of the skin; an absence of a change in treated skin indicates mildness of the applied treatment. 12 weeks
Secondary Stable skin pH during 12 week study •pH Measurements at baseline and weeks 4, 8, and 12. A stable pH measurement reflects that the test product does not affect the overall cutaneous pH value. 12 weeks
Secondary Improvement in Epidermal Thickness after 12 weeks versus baseline •OCT Imaging Procedures at baseline and week 12, with image analysis performed at the end of the study using images from baseline and week 12. A change in epidermal thickness indicates improvement. 12 weeks
See also
  Status Clinical Trial Phase
Completed NCT05098912 - Comparing Polydioxanone Thread Embedding Acupuncture and Manual Acupuncture for Nasolabial Fold Reduction N/A
Completed NCT05271136 - A Clinical Study to Evaluate the Efficacy of an Anti-Aging Serum N/A
Completed NCT05096247 - Post Market Study To Collect Efficacy Data For The Treatment Of Wrinkles With A Radiofrequency Device N/A
Completed NCT05097157 - Study To Assess A Radiofrequency Microneedling Device For Dermatologic Conditions N/A
Completed NCT04128046 - The Effect of Platelet-rich Fibrin Matrix on Skin Rejuvenation N/A
Active, not recruiting NCT04727099 - Clinical Evaluation to Demonstrate the Safety and Performance of the Candela PicoWay System™ N/A
Active, not recruiting NCT06140628 - A 28-day Clinical Study on Facial Skin Rejuvenation N/A
Not yet recruiting NCT05524779 - BTL-785F Device for Non-invasive Reduction of Wrinkles and Overall Facial Improvement N/A
Completed NCT05514782 - A Clinical Study to Evaluate the Long-Term Efficacy and Tolerability of a Daily Anti-Aging Daily Serum N/A
Completed NCT06123572 - A Clinical Study to Assess the Safety and Effectiveness of Anti-Ageing and Skin Brightening Gel N/A
Recruiting NCT04989361 - Soluble Hyaluronic Acid Microneedle VS. Non-ablative Fractional Laser on Infraorbital Wrinkles. N/A
Recruiting NCT04540900 - A Phase I Study of KB301, a Replication-Incompetent, Non-Integrating Vector Expressing Human Type III Collagen (COL3) for the Treatment of Superficial Skin Depressions Phase 1
Recruiting NCT06202274 - Clinical Study to Evaluate the Safety and Efficacy of Candela Technology N/A
Recruiting NCT06074276 - The Effects of Almond on Facial Skin Collagen and Wrinkles N/A
Completed NCT06366503 - Evaluating Procedure Pairing of a Post-Procedure Cream Versus a Comparator in Patients Treated With Fractional Ablative CO2 Laser for Facial Rejuvenation N/A
Active, not recruiting NCT06219278 - A Retrospective Review Evaluating the Matrix Pro Applicator for Treatment of Wrinkles N/A
Active, not recruiting NCT06192550 - Functional Usability and Feasibility Testing of the Profound Matrix™ System N/A
Completed NCT04650620 - Study to Evaluate the Performance and Safety of the Medical Device Plenhyage® N/A
Completed NCT03729700 - The Effect of Almonds on Facial Aesthetics and Modulation of the Microbiome and Lipidome N/A
Completed NCT05102617 - Post Market Usability Evaluation Of The PicoSure Pro Device N/A